Skip to main content
Log in

Patients’ Vehicle Preference for Corticosteroid Treatments of Scalp Psoriasis

  • Current Opinion
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Topical therapy is one of the foundations of dermatology. The vehicles used to deliver topical therapy have considerable impact on efficacy. The vehicle can have direct effects on disease; it can impact the delivery of the active drug, and its characteristics affect patient compliance. While the physical chemistry of vehicles has been studied in great detail, there has been very little study of patients’ preferences for different vehicles and even less on the effect of these preferences on patient compliance. Such study is essential, as noncompliance with topical therapy is very common, and likely impacts the response to topical therapy observed in clinical practice. This manuscript discusses information on patients’ preferences for different vehicles, focussing on the treatment of scalp psoriasis. Significant vehicle characteristics such as ease or difficulty of use, messiness, odors, and staining are recognized to affect patients’ preferences. An instrument based on these characteristics has been used to compare patients’ preferences for different vehicles. Patients with psoriasis generally prefer less messy vehicles, such as foam and solution preparations, to traditional cream and ointment vehicles. These preferences have the potential to impact patient compliance. Studies directly measuring patient compliance have not yet been performed. In conclusion, the choice of vehicles impacts both the potency of the medication and patients’ acceptance of the treatment. Actual effects of different vehicles on compliance are important but have not yet been adequately studied.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Notes

  1. Use of tradenames is for product identification only and does not imply endorsement.

References

  1. Ehmann CW. Dermatological drug development. Arch Dermatol 1988; 124 (6): 950–951

    Article  PubMed  CAS  Google Scholar 

  2. Stoughton RB. Percutaneous absorption of drugs. Annu Rev Pharmacol Toxicol 1989; 29: 55–69

    Article  PubMed  CAS  Google Scholar 

  3. McMichael A, Feldman SR. How to treat common scalp dermatoses. Skin Aging 1999; 7: 44–52

    Google Scholar 

  4. Franz TJ, Parsell DA, Myers JA, et al. Clobetasol propionate foam 0.05 %: a novel vehicle with enhanced delivery. Int J Dermatol 2000; 39: 521–538

    Article  Google Scholar 

  5. Olsen EA, Cram DL, Ellis CN, et al. A double-blind, vehicle-controlled study of clobetasol propionate 0.0 5% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol 1991; 24: 443–447

    Article  PubMed  CAS  Google Scholar 

  6. Katz HI, Lindholm JS, Weiss JS, et al. Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis. Clin Ther 1995; 17: 390–401

    Article  PubMed  CAS  Google Scholar 

  7. Rapp SR, Exum ML, Reboussin DM, et al. The physical, psychological and social impact of psoriasis. J Health Psychol 1997; 2: 525–537

    Article  PubMed  CAS  Google Scholar 

  8. Rapp SR, Feldman SR, Fleischer Jr AB, et al. Health related quality of life in psoriasis: a biopsychosocial model and measures. In: Rajagopalan R, Sherertz EF, Anderson R. Care management of skin diseases: life quality and economic impact. New York: Marcel Dekker Inc, 1998: 125-45

    Google Scholar 

  9. Housman TS, Mellen B, Rapp SR, et al. Psoriasis patients prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis 2002; 70 (6): 327–332

    PubMed  Google Scholar 

  10. Richards HL, Fortune DG, O’Sullivan TM, et al. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999; 41: 581–583

    PubMed  CAS  Google Scholar 

  11. Balkrishnan R, Carroll CL, Camacho FT, et al. Electronic monitoring of medication adherence in skin disease: results of a pilot study in psoriasis. J Am Acad Dermatol. In press

  12. Herz G, Blum G, Yawalkar S. Halobetasol propionate cream by day and halobetasol propionate ointment at night for the treatment of pediatric patients with chronic, localized plaque psoriasis and atopic dermatitis. J Am Acad Dermatol 1991 Dec; 25 (6 Pt 2): 1166–1169

    Article  CAS  Google Scholar 

  13. George YA, Ravis SM, Gottlieb J, et al. Betamethasone Valerate 0.12 % in Foam Vehicle for Scalp Seborrheic Dermatitis in African Americans. Cosmet Dermatol 2002; 15 (7): 23–27

    Google Scholar 

  14. Housman TS, McMichael AJ, Mellen BG, et al. Use of 0.12 % betamethasone valerate foam vs 0.0 1% fluocinolone acetonide topical oil to treat scalp psoriasis: quantitative assessment of patient preference and treatment efficacy. Cosmet Dermatol 2002; 15 (11): 27–30

    Google Scholar 

  15. Bikowski J. The use of therapeutic moisturizers in various dermatologic disorders. Cutis 2001; 68 (5 Suppl.): 3–11

    PubMed  CAS  Google Scholar 

  16. Stein LF, Sherr A, Solodkina G, et al. Betamethasone valerate foam for treatment of nonscalp psoriasis. J Cutan Med Surg 2001; 5: 303–307

    Article  PubMed  CAS  Google Scholar 

  17. Feldman SR, Ravis SM, Fleischer Jr AB, et al. Betamethasone valerate in foam vehicle is effective with both daily and twice a day dosing: a single-blind, open-label study in the treatment of scalp psoriasis. J Cutan Med Surg 2001; 5: 386–389

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Dr Feldman has received grant support from Connetics Corporation.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Feldman, S.R., Housman, T.S. Patients’ Vehicle Preference for Corticosteroid Treatments of Scalp Psoriasis. Am J Clin Dermatol 4, 221–224 (2003). https://doi.org/10.2165/00128071-200304040-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128071-200304040-00001

Keywords

Navigation